{"id":13210,"date":"2021-08-25T18:42:51","date_gmt":"2021-08-25T13:12:51","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=13210"},"modified":"2021-10-05T18:01:02","modified_gmt":"2021-10-05T12:31:02","slug":"top-pharma-companies-by-revenue","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue","title":{"rendered":"Top 7 Pharma Industry Leaders in 2020 By the Numbers"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69dcd5233e324\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69dcd5233e324\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#1_Johnson_Johnson\" >1. Johnson &amp; Johnson&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Deep_dive_into_J_J_portfolio_based_on_revenue_shares_in_2020\" >Deep dive into J&amp;J portfolio based on revenue shares in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Johnson_and_Johnson_Blockbuster_Drugs_in_2020\" >Johnson and Johnson Blockbuster Drugs in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Johnson_and_Johnson_Pharmaceutical_Pipeline-_Key_Events_in_2020\" >Johnson and Johnson Pharmaceutical Pipeline- Key Events in 2020&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#2_Roche\" >2. Roche<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Deep_dive_into_Roche_portfolio_based_on_revenue_shares_in_2020\" >Deep dive into Roche portfolio based on revenue shares in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Roche_Blockbuster_Drugs_in_2020\" >Roche Blockbuster Drugs in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Roche_Pharmaceuticals_Clinical_Pipeline\" >Roche Pharmaceuticals Clinical Pipeline&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#3_Novartis\" >3. Novartis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Deep_dive_into_Novartis_portfolio_based_on_revenue_shares_in_2020\" >Deep dive into Novartis portfolio based on revenue shares in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Novartis_Blockbuster_Drugs_in_2020\" >Novartis Blockbuster Drugs in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Novartis_Pipeline_in_Phase_III\" >Novartis Pipeline in Phase III<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#4_Merck_and_Company\" >4. Merck and Company<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Deep_dive_into_Merck_and_Co_portfolio_based_on_revenue_shares_in_2020\" >Deep dive into Merck and Co. portfolio based on revenue shares in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Merck_and_Co_Blockbuster_Drugs_in_2020\" >Merck and Co. Blockbuster Drugs in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Merck_and_Co_Pipeline\" >Merck and Co. Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#5_AbbVie\" >5. AbbVie<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Deep_dive_into_AbbVie_portfolio_based_on_revenue_shares_in_2020\" >Deep dive into AbbVie portfolio based on revenue shares in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#AbbVie_Blockbuster_Drugs_in_2020\" >AbbVie Blockbuster Drugs in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#AbbVie_R_D_Pipeline\" >AbbVie R&amp;D Pipeline&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#6_Sanofi\" >6. Sanofi<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Deep_dive_into_Sanofi_portfolio_based_on_revenue_shares_in_2020\" >Deep dive into Sanofi portfolio based on revenue shares in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Sanofi_Blockbuster_Drugs_in_2020\" >Sanofi Blockbuster Drugs in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Sanofi_Pipeline\" >Sanofi Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#7_Pfizer\" >7. Pfizer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Deep_dive_into_Pfizer_portfolio_based_on_revenue_shares_in_2020\" >Deep dive into Pfizer portfolio based on revenue shares in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Pfizer_Blockbuster_Drugs_in_2020\" >Pfizer Blockbuster Drugs in 2020<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Pfizer_Pipeline_Summary\" >Pfizer Pipeline Summary&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\/#Way_Ahead\" >Way Ahead<\/a><\/li><\/ul><\/nav><\/div>\n\n<p id=\"h-pharmaceutical-companies-play-a-vital-part-in-our-lives-and-in-helping-us-to-live-healthier-lives-the-pharmaceutical-industry-finds-develops-manufactures-and-promotes-medicines-or-pharmaceutical-drugs-for-usage-as-medications-that-are-administered-or-self-administered-to-patients-in-order-to-cure-vaccinate-or-relieve-symptoms-pharmaceutical-companies-may-deal-in-both-generic-and-brand-name-drugs-as-well-as-medical-devices-they-are-governed-by-a-number-of-rules-and-regulations-that-govern-drug-patenting-testing-safety-efficacy-and-marketing\">Pharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, or relieve symptoms. Pharmaceutical companies may deal in both generic and brand-name drugs as well as medical devices. They are governed by a number of rules and regulations that govern drug patenting, testing, safety, efficacy, and marketing.&nbsp;<\/p>\n\n\n\n<p>The global healthcare spending in 2020 was <strong>USD 8.3 trillion<\/strong> and it is expected to increase to <strong>USD 8.8 trillion<\/strong> in 2021. Whereas the cost of drug development is rising by <strong>10%<\/strong> every year, this is because pharmaceutical drugs are in such high demand all across the world that even during a recession, the pharmaceutical industry remains unaffected. There are a plethora of successful pharmaceutical firms across the globe. Let\u2019s take a look at the most prominent pharmaceutical firms globally by revenue in 2020.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-1-johnson-johnson\"><span class=\"ez-toc-section\" id=\"1_Johnson_Johnson\"><\/span><strong>1. Johnson &amp; Johnson&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Johnson &amp; Johnson (J&amp;J) is an American pharmaceutical company founded in 1886. Johnson and Johnson\u2019s headquarter is in New Brunswick, New Jersey, and the consumer division is in Skillman, New Jersey. The company offers a variety of products under the three major business divisions i.e. <strong>Pharmaceutical, Medical Devices, and Consumer Health.<\/strong> The key focus areas under the pharmaceuticals are Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension. The J&amp;J key focus areas in medical devices include Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular), and Eye Health. While for consumer health, the company focuses on Skin health\/beauty, over-the-counter medicines, baby care, oral care, women\u2019s health, and wound care.&nbsp;<\/p>\n\n\n\n<p>Johnson &amp; Johnson is one of the most profitable firms in the world. It generated a whopping revenue of <strong>USD 82.5 billion<\/strong> in the year 2020 and spent <strong>USD 12.2 billion<\/strong> in R&amp;D. The Pharmaceutical division generated the highest revenue of <strong>USD 45.6 billion<\/strong> in 2020, followed by the Medical Devices (USD 23 billion) and Consumer Health (USD 14.1 billion).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deep-dive-into-j-j-portfolio-based-on-revenue-shares-in-2020\"><span class=\"ez-toc-section\" id=\"Deep_dive_into_J_J_portfolio_based_on_revenue_shares_in_2020\"><\/span><strong>Deep dive into J&amp;J portfolio based on revenue shares in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major sectors that contributed the most to Johnson and Johnson and generated the highest revenue in 2020 amongst all were <strong>Immunology (USD 15 billion) and Oncology (USD 12.3 billion),<\/strong> contributing <strong>18%<\/strong> and <strong>15% <\/strong>respectively to the total revenue. Apart from these, the other sectors that generated revenue for J&amp;J in pharmaceuticals were Neuroscience (USD 6.5 billion), Infectious Disease (USD 3.5 billion), Cardiovascular and Metabolism (USD 4.8 billion), and Pulmonary Hypertension (USD 3.1 billion).<\/p>\n\n\n\n<p>In Medical Devices, Surgery (USD 8 billion) was the primary contributing sector, followed by Orthopedics (USD 7.7 billion), Vision (USD 3.9 billion), and Interventional Solutions (USD 3 billion).&nbsp; From consumer health, Johnson and Johnson generated the highest revenue from Over-the-Counter medicines (USD 4.8 billion) followed by Skin Health (USD 4.4 billion), Oral Care (USD 1.6 billion), Baby Care (USD 1.5 billion), Women\u2019s Health (USD 0.9 billion), and Wound Care (USD 0.7 billion).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-johnson-and-johnson-blockbuster-drugs-in-2020\"><span class=\"ez-toc-section\" id=\"Johnson_and_Johnson_Blockbuster_Drugs_in_2020\"><\/span><strong>Johnson and Johnson Blockbuster Drugs<\/strong> <strong>in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Johnson and Johnson manufactures a variety of drugs to treat several indications. Among all of these drugs, <strong>Stelara (Ustekinumab),<\/strong> approved to treat Crohn\u2019s Disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis, generated the highest revenue of approximately <strong>USD 7.7 billion, <\/strong>&nbsp;making up <strong>9.3%<\/strong> revenue share of the drug in 2020. The second blockbuster J&amp;J drug that made a profit of <strong>USD 4.2 billion<\/strong> was <strong>DARZALEX (Daratumumab), <\/strong>used to treat patients with multiple myeloma. The other J&amp;J drugs that generated a good revenue in 2020 were <a href=\"https:\/\/www.delveinsight.com\/report-store\/imbruvica-ibrutinib-drug-insight-market-forecast\"><strong>Imbruvica (Ibrutinib)<\/strong><\/a> <strong>(USD 4.1 billion)<\/strong> used for Chronic lymphocytic leukemia, small lymphocytic lymphoma, and others, <strong>Remicade (Infliximab) (USD 3.7 billion)<\/strong> used for Crohn\u2019s Disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis, and others, and <strong>Zytiga (Abiraterone acetate) (USD 2.4 billion)<\/strong> used to treat metastatic castration-resistant prostate cancer.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-johnson-and-johnson-pharmaceutical-pipeline-key-events-in-2020\"><span class=\"ez-toc-section\" id=\"Johnson_and_Johnson_Pharmaceutical_Pipeline-_Key_Events_in_2020\"><\/span><strong>Johnson and Johnson Pharmaceutical Pipeline- Key Events in 2020<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Johnson and Johnson are evaluating a variety of drugs for several indications that may soon join the respective market in the upcoming years. There are several J&amp;J drugs that are in the pipeline for potential US\/EU approvals for different indications, and around 4 drugs got the EU approval, 1 got the US approval while <strong>Imbruvica <\/strong>(for frontline CLL combo with Rituximab) got both EU and US approvals.&nbsp;<\/p>\n\n\n\n<p>There are around 8 drugs also which are in planned submission for the US\/EU, including <strong>Ciltacabtagene Autoleucei<\/strong> <strong>(BCMA CAR-T)<\/strong> for multiple myeloma and <strong>Amivantamab (EGFR\/cMET)<\/strong> for Non-Small Cell Lung Cancer. Apart from these, <strong>Xarelto <\/strong>(for PAD) and Darzalex (for Amyloidosis and Refractory Multiple Myeloma) are in Phase III of clinical trials, while <strong>Tremfya<\/strong> (for Crohn\u2019s Disease), <strong>Seltorexant <\/strong>(for insomnia), and <strong>Ciltacabtagene Autoleucei<\/strong> <strong>(BCMA CAR-T)<\/strong> (for multiple myeloma) are in Phase II of development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2-roche\"><span class=\"ez-toc-section\" id=\"2_Roche\"><\/span><strong>2. Roche<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>F. Hoffmann-La Roche AG is a Swiss multinational pharmaceutical and diagnostics firm with operations all over the world. The company is located in Basil and was founded in 1896. Roche is the world&#8217;s leading pharmaceutical company in cancer care. The company works under its two main business divisions- <strong>Pharmaceuticals and Diagnostics. <\/strong>The key areas of focus in pharmaceuticals include Immunology, Infectious Diseases, Neuroscience, Oncology, Ophthalmology, Hemophilia A, and Other therapeutic areas. While in diagnostics, the company focuses on Centralized and Point of Care Solutions, Molecular Diagnostics, Diabetes Care, and Tissue Diagnostics.<\/p>\n\n\n\n<p>After J&amp;J, Roche generated the highest revenue of <strong>USD 62.2 billion<\/strong> in 2020. Roche is the second-biggest spender on research and development, with an investment of <strong>USD 13 billion<\/strong> in the year 2020. Pharmaceuticals is the major division for Roche in terms of generating revenue. Around <strong>USD 44.5 billion<\/strong> revenue was generated by the pharmaceuticals division and the rest <strong>USD 13.7 billion<\/strong> was by diagnostics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deep-dive-into-roche-portfolio-based-on-revenue-shares-in-2020\"><span class=\"ez-toc-section\" id=\"Deep_dive_into_Roche_portfolio_based_on_revenue_shares_in_2020\"><\/span><strong>Deep dive into Roche portfolio based on revenue shares in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major sectors that contributed the most to Roche and generated the highest revenue in 2020 amongst all were <strong>Oncology and Immunology.<\/strong> Oncology generated a massive revenue of <strong>USD 23.82 billion, <\/strong>while Immunology generated a revenue of <strong>USD 8.77 billion<\/strong>. The combined sales of the Immunology (15%) and Oncology (38%) sectors were more than 50% of the total revenue in 2020. The other sectors in pharmaceuticals that contributed to the revenue include Neuroscience (USD 5.25 billion), Infectious Disease (USD 0.86 billion), Hemophilia A (USD 2.19 billion), Ophthalmology (USD 1.4 billion), and Other therapeutic areas (USD 3.7 billion).&nbsp;<\/p>\n\n\n\n<p>For the Roche Diagnostics division, the highest revenue was generated through Centralized and Point of Care Solutions (USD 7.7 billion), followed by Molecular Diagnostics (USD 4 billion), Diabetes Care (USD 1.7 billion), and Tissue Diagnostics (USD 1.1 billion).&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-blockbuster-drugs-in-2020\"><span class=\"ez-toc-section\" id=\"Roche_Blockbuster_Drugs_in_2020\"><\/span><strong>Roche Blockbuster Drugs in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Roche is strong in the area of pharmaceuticals for cancer care; therefore, there are several drugs that are used to treat patients with different types of cancer. <strong>AVASTIN (Bevacizumab)<\/strong>, used to treat Metastatic Colorectal Cancer, Breast, Lung, Kidney, Cervical, and Ovarian Cancer, <a href=\"https:\/\/www.delveinsight.com\/report-store\/recurrent-glioblastoma-market\"><strong>Relapsed Glioblastoma<\/strong><\/a>, and Liver Cancer, came out as the blockbuster drug for Roche in 2020 by generating the highest revenue of <strong>USD 4.9 billion <\/strong>and an<strong> 8.5%<\/strong> revenue share, which was the highest among all Roche\u2019s drugs. <strong>OCREVUS (Ocrelizumab)<\/strong> used for treating multiple myeloma, was not far behind Avastin and generated a revenue share of <strong>7.3% (USD 4.3 billion). <\/strong>There was a close competition between <strong>PERJETA (Pertuzumab)<\/strong> (for Chronic lymphocytic leukemia, small lymphocytic lymphoma, and others) and <strong>Herceptin (Trastuzumab)<\/strong> (for HER2 overexpressing breast and metastatic gastric cancer). They both made a sale of <strong>USD 3.8 billion and USD 3.7 billion,<\/strong> respectively. <strong>Rituxan (Rituximab), <\/strong>which is used for treating Non-Hodgkin\u2019s Lymphoma, Chronic lymphocytic leukemia, and Rheumatoid Arthritis, generated a revenue share of <strong>5.4% (USD 3.2 billion).<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-pharmaceuticals-clinical-pipeline\"><span class=\"ez-toc-section\" id=\"Roche_Pharmaceuticals_Clinical_Pipeline\"><\/span><strong>Roche Pharmaceuticals Clinical Pipeline<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Roche received authorizations for four new medicines in 2020, and it is the only pharmaceutical company that had a record number of 19 new drugs in registrational studies or filed for approval. The new approvals include <strong>Enspryng <\/strong>(for Neuromyelitis Optica Spectrum Disorder), <strong>Evrysdi <\/strong>(for Spinal muscular atrophy), <strong>Gavreto <\/strong>(Metastatic RET-altered non-small cell lung cancer), and <strong>Phesgo <\/strong>(for Early and metastatic HER2-positive breast cancer). Apart from these, Roche has a robust pipeline in Oncology with 1 drug in the registration phase, 7 in Phase III, 3 in Phase II, and 28 in Phase I. After oncology, the Neuroscience sector has the highest number of therapies in the pipeline including 2 in the registration phase, 3 in Phase III, 5 in Phase II, and 6 in Phase I followed by the other sectors such as Inflammation\/Immunology which have 2 therapies in phase III, 5 in Phase II, and 6 in Phase I, Ophthalmology has 1 therapy in the registration phase, 1 in Phase III, 4 in Phase II, and 6 in Phase I, Infectious Disease has 2 therapies in Phase III, 3 in Phase II, and 3 in Phase I, and Metabolics and others has 2 therapies in Phase II, and 2 in Phase I.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-3-novartis\"><span class=\"ez-toc-section\" id=\"3_Novartis\"><\/span><strong>3. Novartis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novartis is a Switzerland-based multinational pharmaceutical company headquartered in Basel. It is among the world&#8217;s biggest pharmaceutical companies. The company was founded in 1996. Novartis operates through its two main business divisions- <strong>Innovative Medicines Division and Sandoz Division.<\/strong> The Innovative Medicines Division focuses on Oncology, Immunology, Hepatology, Dermatology, Ophthalmology, Neuroscience, Cardiovascular, Renal and Metabolism, and Respiratory. While the Sandoz Division deals in Retail Generics, Biopharmaceuticals, and Anti-Infectives.&nbsp;<\/p>\n\n\n\n<p>The annual sale of Novartis in the year 2020 was <strong>USD 48.6 billion<\/strong> and it has spent around <strong>USD 8.9 billion<\/strong> in its R&amp;D. Novartis is mainly dependent on its Innovative Medicines Division and as a result, <strong>80% (USD 39 billion)<\/strong> of the total revenue is generated through its Innovative Medicines Division only. Sandoz Division contributed only <strong>USD 9.6 billion<\/strong> to the total revenue.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deep-dive-into-novartis-portfolio-based-on-revenue-shares-in-2020\"><span class=\"ez-toc-section\" id=\"Deep_dive_into_Novartis_portfolio_based_on_revenue_shares_in_2020\"><\/span><strong>Deep dive into Novartis portfolio based on revenue shares in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major sector that contributed the most in 2020 to Novartis was <strong>Oncology<\/strong>. It generated a revenue of <strong>USD 14.71 billion,<\/strong> which was <strong>30%<\/strong> of the total revenue. From the Innovative Medicines Division, the Established Medicines sector contributed USD 6.63 billion followed by the other sectors such as Immunology, Hepatology, and Dermatology (USD 4.86 billion), Ophthalmology (USD 4.41 billion), Neuroscience (USD 4.32 billion), Cardiovascular, Renal, and Metabolism (USD 2.49 billion), Respiratory (USD 1.9 billion).&nbsp;<\/p>\n\n\n\n<p>Among the Sandoz Divison, the Retail Generic sector generated the highest revenue, USD 7.24 billion. The rest of the revenue was contributed by Biopharmaceuticals (USD 1.92 billion) and Anti-Infectives (USD 0.47 billion).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-blockbuster-drugs-in-2020\"><span class=\"ez-toc-section\" id=\"Novartis_Blockbuster_Drugs_in_2020\"><\/span><strong>Novartis Blockbuster Drugs in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novartis manufactured a variety of drugs to treat several indications. The company generated the maximum profit <strong>(USD 3.9 billion)<\/strong> from its drug <strong>Cosentyx (Secukinumab) <\/strong>that is used to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\"><strong>Plaque Psoriasis<\/strong><\/a>, Psoriatic Arthritis, and Ankylosing Spondylitis. This Novartis drug generated around <strong>8.2%<\/strong> of revenue share. Another drug that generated a revenue share of <strong>7.61% (USD 3 billion)<\/strong> was <strong>GILENYA (Fingolimod) <\/strong>used to treat Relapsing forms of multiple sclerosis. <strong>Entresto (Sacubitril and Valsartan), <\/strong>the drug used for heart failure, generating a revenue share of <strong>5.1% (USD 2.4 billion). <\/strong>The drugs <strong>Tasigna (Nilotinib) <\/strong>(for Philadelphia chromosome-positive chronic myeloid leukemia) and <strong>LUCENTIS (Ranibizumab)<\/strong> (for Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion and Diabetic Macular Edema) generated approximately the same revenue i.e., <strong>4% (USD 1.95 billion) and 3.9% (USD 1.93 billion)<\/strong> respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-pipeline-in-phase-iii\"><span class=\"ez-toc-section\" id=\"Novartis_Pipeline_in_Phase_III\"><\/span><strong>Novartis Pipeline in Phase III<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novartis is generating the highest revenue through its oncology sectors and therefore, it is focusing more on oncology. There are 12 therapies that are in pipeline in Oncology, which is the maximum as compared to any other therapeutic area. After Oncology, Cardiovascular, Renal, and Metabolism have the highest number of therapies (3) in the pipeline. Neuroscience and Immunology, Hepatology, and Dermatology sectors have 2 therapies each in the pipeline. In contrast, the sectors such as Ophthalmology, Biosimilars, and Global Health have only 1 therapy in the pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-4-merck-and-company\"><span class=\"ez-toc-section\" id=\"4_Merck_and_Company\"><\/span><strong>4. Merck and Company<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck &amp; Co. was founded in 1891 and is now one of the world&#8217;s largest pharmaceutical companies. The headquarters of this American multinational pharmaceutical company is in Kenilworth, New Jersey. The company deals in its two business divisions- <strong>Pharmaceuticals and Animal Health.<\/strong> In the pharmaceuticals division, the company focuses on the areas such as Oncology, Vaccines, Immunology, Hospital Acute Care, Neuroscience, Cardiovascular, Virology, Diabetes, and Women\u2019s Health. Through its animal health division, it deals in Veterinary Pharmaceuticals and Vaccines (Livestock and Companion Animal Products).&nbsp;&nbsp;<\/p>\n\n\n\n<p>The annual sale of Merck and Company in the year 2020 was <strong>USD 47.9 billion. <\/strong>The corporation is the world&#8217;s biggest spender on pharmaceutical research and development among all the other pharmaceutical companies. It spent <strong>USD 13.6 billion<\/strong> in research and development. Approximately <strong>90% (USD 43 billion) <\/strong>of the total revenue was generated from its Pharmaceutical division, whereas around <strong>USD 4.7 billion<\/strong> was contributed by the Animal Health division.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deep-dive-into-merck-and-co-portfolio-based-on-revenue-shares-in-2020\"><span class=\"ez-toc-section\" id=\"Deep_dive_into_Merck_and_Co_portfolio_based_on_revenue_shares_in_2020\"><\/span><strong>Deep dive into Merck and Co. portfolio based on revenue shares in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major sector that contributed the most to Merck and Co. in 2020 was <strong>Oncology. <\/strong>The oncology sector made up to <strong>33% (USD 15.8 billion)<\/strong> of the total revenue among all the other sectors. Merck and Co. generated a revenue of USD 6.9 billion through the vaccines. Diabetes contributed USD 5.2 billion followed by Hospital Acute Care (USD 2 billion), Cardiovascular (17 billion), Immunology (1.1 billion), Virology (1 billion), and Women\u2019s Health (0.9 billion).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-merck-and-co-blockbuster-drugs-in-2020\"><span class=\"ez-toc-section\" id=\"Merck_and_Co_Blockbuster_Drugs_in_2020\"><\/span><strong>Merck and Co. Blockbuster Drugs in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck and Co. are generating the maximum profits from the sale of its oncological drugs, and as a result, <strong>KEYTRUDA (Pembrolizumab)<\/strong>, Merck\u2019s drug used to treat multiple types of cancers, became the highest-grossing drug in 2020, generating approximately <strong>USD 14.3 billion, <\/strong>making up <strong>29.9%<\/strong> revenue share of the drug. Apart from oncological drugs, Merck and Co. vaccine, <strong>GARDASIL (Human Papillomavirus quadrivalent and 9-valent Vaccine)<\/strong> used for Cancers in women and men caused by various <a href=\"https:\/\/www.delveinsight.com\/report-store\/human-papillomavirus-hpv-market\"><strong>Human Papillomavirus<\/strong><\/a> types also generated a good revenue share of <strong>8.2% (USD 3.9 billion). <\/strong>The diabetic drugs also yielded a good profit amount for Merck and Co. The two diabetic drugs, <strong>Januvia (Sitagliptin) and Janumet (Sitagliptin and metformin HCl) <\/strong>used to treat type 2 diabetes mellitus, generated a revenue share of <strong>6.8% (USD 3.3 billion) and 4.1% (USD 1.9 billion),<\/strong> respectively. Another Merck and Co. vaccine, <strong>PNEUMOVAX 23 (Pneumococcal vaccine polyvalent) <\/strong>used for the prevention of pneumococcal disease caused by the 23 serotypes in the vaccine, generated a revenue share of <strong>2.2% (USD 1 billion).<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-merck-and-co-pipeline\"><span class=\"ez-toc-section\" id=\"Merck_and_Co_Pipeline\"><\/span><strong>Merck and Co. Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck and Co. have a strong pipeline for oncology. Along with the drugs, Merck is also developing vaccines for various indications that are in a different phase of development. There are 23 therapies and vaccines in total that are in Phase II of clinical trials. Among these, <strong>MK-1308 <\/strong>(for cancer melanoma NSCLC solid tumors), <strong>MK-1454 <\/strong>(for cancer head and neck), <strong>MK-4280 <\/strong>(for hematological cancer malignancies NSCLC), <strong>MK-5890 <\/strong>(for cancer NSCLC), and <strong>MK-7684 <\/strong>(for cancer NSCLC melanoma) are being developed in combination with Keytruda. Around 8 therapies are in Phase III of clinical trials, among which <strong>MK-7902 <\/strong>(for cancer bladder endometrial, HNSCC melanoma, NSCLC gastric) and <strong>MK-7339 <\/strong>(used for <a href=\"https:\/\/www.delveinsight.com\/blog\/biomarkers-in-non-small-cell-lung-cancer-therapy-market\"><strong>cancer NSCLC<\/strong><\/a>, colorectal SCLC) are being developed in combination with Keytruda.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-5-abbvie\"><span class=\"ez-toc-section\" id=\"5_AbbVie\"><\/span><strong>5. AbbVie<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AbbVie is a biopharmaceutical company headquartered in North Chicago, Illinois, United States. AbbVie was established in 2013 as a distinct company from Abbott. AbbVie works through its only one business division i.e. <strong>Medicines and Therapies.<\/strong> Oncology, Immunology, Eye Care, Neuroscience, Women\u2019s Health, Aesthetics, and others are among the key therapeutic areas in which the company focuses through its medicines and therapies division.&nbsp;<\/p>\n\n\n\n<p>The total sale generated by the company in 2020 was <strong>USD 45.8 billion <\/strong>and invested <strong>USD 6.5 billion<\/strong> in the research and development.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deep-dive-into-abbvie-portfolio-based-on-revenue-shares-in-2020\"><span class=\"ez-toc-section\" id=\"Deep_dive_into_AbbVie_portfolio_based_on_revenue_shares_in_2020\"><\/span><strong>Deep dive into AbbVie portfolio based on revenue shares in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major sector that contributed the most to AbbVIe in 2020 was <strong>Immunology. <\/strong>The Immunology sector contributed <strong>48% (USD 22.15 billion)<\/strong> of the total revenue. The other sector that generated the most revenue after immunology was Hematological Oncology. It generated a revenue of USD 6.65 billion. Apart from these, the other sectors that contributed to the revenue include Aesthetics (USD 2.59 billion), Neuroscience (USD 2.42 billion), Eye Care (USD 2.18 billion), and Women\u2019s Health (USD 0.67 billion). At the same time, the other key products generated a revenue of USD 4.02 billion.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-blockbuster-drugs-in-2020\"><span class=\"ez-toc-section\" id=\"AbbVie_Blockbuster_Drugs_in_2020\"><\/span><strong>AbbVie Blockbuster Drugs in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The company has been enjoying a monopoly in the market for a long time, with the best-selling drug HUMIRA under its umbrella. They are generating a massive amount of revenue from HUMIRA itself. <a href=\"https:\/\/www.delveinsight.com\/report-store\/adalimumab-biosimilars-insight\"><strong>HUMIRA (Adalimumab)<\/strong><\/a> is used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn\u2019s Disease, Ulcerative Coliti, and others. In the year 2020, Humira generated a revenue share of nearly around <strong>43.3% (USD 19.8 billion),<\/strong> which was the highest among all the other AbbVie drugs. After Humira, the drug that the company depends on is <strong>Imbruvica (Ibrutinib)<\/strong> which is used to treat Chronic lymphocytic leukemia, Mantle cell lymphoma, Waldenstr\u00f6m\u2019s macroglobulinemia, and others. Imbruvica contributed <strong>USD 5.3 billion<\/strong>, around <strong>11.5%<\/strong> of revenue share. Other AbbVie drugs didn\u2019t get as much revenue as Humira and Imbruvica. <strong>MAVYRET (Glecaprevir and pibrentasvir)<\/strong> (for Chronic HCV genotype), <strong>Skyrizi (Risankizumab)<\/strong> (for plaque psoriasis), and <strong>VENCLEXTA (Venetoclax)<\/strong> (for Chronic lymphocytic leukemia, and Acute Myeloid Leukemia) generated nearly same amount of revenue share i.e.<strong> 0.3% (USD 1.8 billion), 0.3% (1.5 billion), and 0.2% (1.3 billion)<\/strong> respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-r-d-pipeline\"><span class=\"ez-toc-section\" id=\"AbbVie_R_D_Pipeline\"><\/span><strong>AbbVie R&amp;D Pipeline<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AbbVie has a robust pipeline, mainly in oncology and immunology. However, AbbVie is pacing up the trials of its other drug assets as the patent expiration for Humira is approaching fast. AbbVie\u2019s immunological drug, <strong>Rinvoq (upadacitinib)<\/strong> is approved for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Atopic Dermatitis and is in the late stages of Crohn\u2019s Disease and Ulcerative Colitis. There are 15 drugs in the registrational\/Phase III including its another important immunological drug, <strong>Skyrizi (risankizumab)<\/strong> which is approved for <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-market\"><strong>Psoriasis<\/strong><\/a>, but in the mid-to-late stage clinical development for Psoriatic Arthritis, Crohn\u2019s Disease, and Ulcerative Colitis. Apart from these, there are 16 drugs that are in the phase II stage of development, and 35 are in Phase I. Among them, oncology has 26 drugs in the pipeline in both phases, followed by immunology (8), neuroscience (8), targeted investment (5), eye care (4), and aesthetics (2).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-6-sanofi\"><span class=\"ez-toc-section\" id=\"6_Sanofi\"><\/span><strong>6. Sanofi<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sanofi is a global pharmaceutical company based in Paris, France. Sanofi-Synth\u00e9labo was founded in 1973 and merged with Synth\u00e9labo in 1999 to become Sanofi-Synth\u00e9labo. Sanofi-Synth\u00e9labo merged with Aventis in 2004 and was renamed Sanofi-Aventis. In May 2011, the company renamed itself Sanofi. Sanofi has three main business divisions- <strong>Pharmaceuticals, Vaccines, and Consumer Healthcare.<\/strong> The Pharmaceutical division of Sanofi deals in Speciality Care and General Medicines. The Sanofi\u2019s Vaccines division focuses on Poliomyelitis, Pertussis, and Haemophilus influenza Type B (Hib) pediatric vaccines, Influenza vaccines, Adult booster vaccines, Meningitis vaccines, Travel, and endemic vaccines. The Consumer Healthcare division of Sanofi has now become a standalone commercial entity with its own manufacturing and R&amp;D capabilities.&nbsp;<\/p>\n\n\n\n<p>The total sale generated by Sanofi in the year 2020 was <strong>USD 42.5 billion<\/strong> and spent <strong>USD 6.5 billion<\/strong> in research and development. The Pharmaceuticals division of Sanofi is the main division of the company in terms of sales. It generated a revenue of <strong>USD 30.33 billion,<\/strong> which was the maximum as compared to the rest of the other divisions i.e, Vaccines (<strong>USD 7.05 billion<\/strong>) and Consumer Healthcare (<strong>USD 5.19 billion<\/strong>).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deep-dive-into-sanofi-portfolio-based-on-revenue-shares-in-2020\"><span class=\"ez-toc-section\" id=\"Deep_dive_into_Sanofi_portfolio_based_on_revenue_shares_in_2020\"><\/span><strong>Deep dive into Sanofi portfolio based on revenue shares in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major sector that contributed the most to Sanofi\u2019s wealth in 2020 was <strong>Cardiovascular and Established Prescription Products.<\/strong> It contributed <strong>27% (USD 11.82 billion)<\/strong> of the total revenue. The other sectors through which Sanofi able to get some revenue include Diabetes (USD 5.56 billion), Rare Disease (USD 3.55 billion), Multiple Sclerosis, Neurology, Other Inflammatory Diseases and Immunology (USD 2.82 billion), Rare Blood Disorders (USD 1.43 billion), and Oncology (USD 0.94 billion).&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-blockbuster-drugs-in-2020\"><span class=\"ez-toc-section\" id=\"Sanofi_Blockbuster_Drugs_in_2020\"><\/span><strong>Sanofi Blockbuster Drugs in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sanofi produces a variety of drugs in many therapeutics areas to treat numerous diseases, but <a href=\"https:\/\/www.delveinsight.com\/report-store\/dupilumab-emerging-insight-and-market-forecast\"><strong>DUPIXENT (Dupilumab)<\/strong><\/a> came out as its main drug as the maximum revenue in 2020 was generated through its sales. Dupixent is used to treat people with Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis. It generated a revenue share of <strong>9.8% (USD 4.2 billion)<\/strong> in 2020. <strong>LANTUS (Insulin glargine)<\/strong> injection used to treat type 1 and 2 diabetes mellitus is another Sanofi product that is not far behind Dupixent. Lantus generated a revenue share of <strong>7.3% (USD 3.2 billion). AUBAGIO (Teriflunomide)<\/strong> used for relapsing forms of multiple sclerosis and <strong>Lovenox (Enoxaparin sodium)<\/strong> used for deep vein thrombosis, are some of Sanofi\u2019s drugs apart from Dupixent and Lantus that generated a decent revenue. They both generated a revenue share of <strong>5.2% (USD 2.4 billion) and 3.7% (USD 1.6 billion)<\/strong> respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-pipeline\"><span class=\"ez-toc-section\" id=\"Sanofi_Pipeline\"><\/span><strong>Sanofi Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sanofi has a strong pipeline in Oncology. There are 18 oncological therapies for several indications that are in the pipeline and are in different stages of development. Among these, 2 therapies are in the registration\/phase III while 4 are in Phase II and 12 are in Phase III. Apart from oncology, therapies for Rare Blood Disorders, Immunology and Inflammation, and Rare Diseases are also in the pipeline. For Rare Blood Disorders, 6 therapies are in pipeline, 3 in registration\/phase III and Phase I each. Like Rare Blood Disorders, for Immunology and Inflammation, and Rare Diseases, 6 therapies are in the pipeline with 2 in the registration\/phase III, 1 in Phase II, and 3 in Phase I, and 2 in the registration\/phase III, 3 in Phase II, and 1 in Phase I respectively. There are 4 therapies in the pipeline for <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\"><strong>Multiple Sclerosis<\/strong><\/a> Neurology, in which 1 is in the registration\/phase III, 3 in Phase II, and 1 in Phase I.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-7-pfizer\"><span class=\"ez-toc-section\" id=\"7_Pfizer\"><\/span><strong>7. Pfizer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer is an American multinational pharmaceutical company founded in 1849. Pfizer\u2019s headquarters is in New York City. It is among the world&#8217;s largest pharmaceutical companies. Pfizer operates through its business division, <strong>Biopharma. <\/strong>Oncology, Inflammation &amp; Immunology, Internal Medicine, Hospital, Vaccines, and Rare Disease all are the focus areas of Pfizer\u2019s Biopharma division.&nbsp;<\/p>\n\n\n\n<p>However, in 2020, the annual sale of Pfizer was the lowest among all the other pharmaceutical companies. The total revenue generated by Pfizer was <strong>USD 41.9 billion,<\/strong> with an investment of <strong>USD 9.4 billion<\/strong> in research and development.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deep-dive-into-pfizer-portfolio-based-on-revenue-shares-in-2020\"><span class=\"ez-toc-section\" id=\"Deep_dive_into_Pfizer_portfolio_based_on_revenue_shares_in_2020\"><\/span><strong>Deep dive into Pfizer portfolio based on revenue shares in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major sector that contributed the most to Pfizer in 2020 was <strong>Oncology. <\/strong>Pfizer\u2019s<strong> <\/strong>Oncology sector generated a revenue of <strong>USD 10.8 billion,<\/strong> which was <strong>25%<\/strong> of the total revenue. The other sector that gave competition to oncology was Internal Medicine. It generated a revenue of USD 9 billion. Apart from these, hospitals (USD 7.9 billion), Vaccines (USD 6.5 billion), Inflammation and Immunology (USD 4.5 billion), and Rare Diseases (USD 2.9 billion) were among the sectors that contributed to the total revenue.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-blockbuster-drugs-in-2020\"><span class=\"ez-toc-section\" id=\"Pfizer_Blockbuster_Drugs_in_2020\"><\/span><strong>Pfizer Blockbuster Drugs in 2020<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer is known for manufacturing both drugs and vaccines. Pfizer\u2019s vaccines are in demand and as a result one of its vaccine, <strong>Prevenar 13 (pneumococcal 13-valent conjugate vaccine)<\/strong> used for invasive diseases caused by <em>Streptococcus pneumoniae, <\/em>generated the maximum revenue from its sale during the year 2020. It generated a revenue share of <strong>13.8% (USD 5.8 billion). <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/ibrance-palbociclib-drug-insight-market-forecast\"><strong>IBRANCE (Palbociclib)<\/strong><\/a><strong>,<\/strong> used to treat HER2-negative advanced or metastatic breast cancer, was not far behind and generated a revenue share of <strong>12.6% (USD 5.3 billion)<\/strong>. Another Pfizer drug in demand was <strong>Eliquis (Apixaban),<\/strong> used for nonvalvular atrial fibrillation and generated a revenue share of <strong>11.6% (USD 4.9 billion).<\/strong> The other two drugs that generated a revenue share of <strong>5.7% (USD 2.4 billion) and 3.1% (USD 1.3 billion) <\/strong>were <strong>XELJANZ (Tofacitinib)<\/strong> (for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis) and <strong>Enbrel (Etanercept)<\/strong> (for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and others) respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-pipeline-summary\"><span class=\"ez-toc-section\" id=\"Pfizer_Pipeline_Summary\"><\/span><strong>Pfizer Pipeline Summary<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer is evaluating several drug candidates to treat various indications and these therapies are expected to launch in the upcoming years and be available in the respective market soon. There are 95 therapies\/vaccines in total in the pipeline. Out of these, 9 therapies\/vaccines are in the registration phase, 24 are in Phase III, while 35 and 27 therapies\/vaccines are in Phase II and Phase I, respectively.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Healthcare market comprises several pharmaceutical and biotech companies; some are established goliaths while many more continue to emerge. A recent trend that follows is the emergence of several start-ups aiming to innovate the healthcare delivery system and therapy approaches. While pharma companies continue to expand with the help of collaborations and mergers, the Healthcare market also is also witnessing a large number of buyouts and spin-offs. Nevertheless, with the rising demand for effective and standard healthcare, increase in healthcare expenditure, and surging focus of global organizations towards procuring better healthcare services to the masses, pharma and biotech companies are expected to flourish and provide better therapies in the coming decade.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, or relieve symptoms. Pharmaceutical companies may deal in both generic [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":13212,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[56,2734,395,423,460,712,469,524,533],"industry":[17225],"therapeutic_areas":[17278],"class_list":["post-13210","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-abbvie","tag-johnson-and-johnson","tag-merck","tag-novartis","tag-pfizer","tag-pharma-industry","tag-pharmaceutical-companies","tag-roche","tag-sanofi","industry-pharmaceutical","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Top Global Pharmaceutical Companies by Revenue<\/title>\n<meta name=\"description\" content=\"In 2020, top global pharmaceutical companies generated significant revenue from drugs sales. Companies such as J&amp;J, Roche, Merck, AbbVie and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Top Global Pharmaceutical Companies by Revenue\" \/>\n<meta property=\"og:description\" content=\"In 2020, top global pharmaceutical companies generated significant revenue from drugs sales. Companies such as J&amp;J, Roche, Merck, AbbVie and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-25T13:12:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-05T12:31:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/25183612\/top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"19 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Top Global Pharmaceutical Companies by Revenue","description":"In 2020, top global pharmaceutical companies generated significant revenue from drugs sales. Companies such as J&J, Roche, Merck, AbbVie and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue","og_locale":"en_US","og_type":"article","og_title":"Top Global Pharmaceutical Companies by Revenue","og_description":"In 2020, top global pharmaceutical companies generated significant revenue from drugs sales. Companies such as J&J, Roche, Merck, AbbVie and","og_url":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-08-25T13:12:51+00:00","article_modified_time":"2021-10-05T12:31:02+00:00","og_image":[{"width":750,"height":420,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/25183612\/top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue","url":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue","name":"Top Global Pharmaceutical Companies by Revenue","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/25183612\/top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide.jpg","datePublished":"2021-08-25T13:12:51+00:00","dateModified":"2021-10-05T12:31:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"In 2020, top global pharmaceutical companies generated significant revenue from drugs sales. Companies such as J&J, Roche, Merck, AbbVie and","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/25183612\/top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/25183612\/top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide.jpg","width":750,"height":420,"caption":"top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/25183612\/top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide-300x168.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pharmaceutical companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical companies<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 25, 2021","modified":"Updated on Oct 5, 2021"},"absolute_dates_time":{"created":"Posted on Aug 25, 2021 6:42 pm","modified":"Updated on Oct 5, 2021 6:01 pm"},"featured_img_caption":"top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=13210"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13210\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/13212"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=13210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=13210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=13210"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=13210"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=13210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}